Cargando…

Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse

Atherosclerosis (AT) is a progressive chronic disease involving lipid accumulation, fibrosis, and inflammation in medium and large-sized arteries, and it is the main cause of cardiovascular disease (CVD). AT is caused by dyslipidemia and mediated by both innate and adaptive immune responses. Despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Badimon, Lina, Suades, Rosa, Arderiu, Gemma, Peña, Esther, Chiva-Blanch, Gemma, Padró, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741657/
https://www.ncbi.nlm.nih.gov/pubmed/29326946
http://dx.doi.org/10.3389/fcvm.2017.00077
_version_ 1783288220574810112
author Badimon, Lina
Suades, Rosa
Arderiu, Gemma
Peña, Esther
Chiva-Blanch, Gemma
Padró, Teresa
author_facet Badimon, Lina
Suades, Rosa
Arderiu, Gemma
Peña, Esther
Chiva-Blanch, Gemma
Padró, Teresa
author_sort Badimon, Lina
collection PubMed
description Atherosclerosis (AT) is a progressive chronic disease involving lipid accumulation, fibrosis, and inflammation in medium and large-sized arteries, and it is the main cause of cardiovascular disease (CVD). AT is caused by dyslipidemia and mediated by both innate and adaptive immune responses. Despite lipid-lowering drugs have shown to decrease the risk of cardiovascular events (CVEs), there is a significant burden of AT-related morbidity and mortality. Identification of subjects at increased risk for CVE as well as discovery of novel therapeutic targets for improved treatment strategies are still unmet clinical needs in CVD. Microvesicles (MVs), small extracellular plasma membrane particles shed by activated and apoptotic cells have been widely linked to the development of CVD. MVs from vascular and resident cells by facilitating exchange of biological information between neighboring cells serve as cellular effectors in the bloodstream and play a key role in all stages of disease progression. This article reviews the current knowledge on the role of MVs in AT and CVD. Attention is focused on novel aspects of MV-mediated regulatory mechanisms from endothelial dysfunction, vascular wall inflammation, oxidative stress, and apoptosis to coagulation and thrombosis in the progression and development of atherothrombosis. MV contribution to vascular remodeling is also discussed, with a particular emphasis on the effect of MVs on the crosstalk between endothelial cells and smooth muscle cells, and their role regulating the active process of AT-driven angiogenesis and neovascularization. This review also highlights the latest findings and main challenges on the potential prognostic, diagnostic, and therapeutic value of cell-derived MVs in CVD. In summary, MVs have emerged as new regulators of biological functions in atherothrombosis and might be instrumental in cardiovascular precision medicine; however, significant efforts are still needed to translate into clinics the latest findings on MV regulation and function.
format Online
Article
Text
id pubmed-5741657
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57416572018-01-11 Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse Badimon, Lina Suades, Rosa Arderiu, Gemma Peña, Esther Chiva-Blanch, Gemma Padró, Teresa Front Cardiovasc Med Cardiovascular Medicine Atherosclerosis (AT) is a progressive chronic disease involving lipid accumulation, fibrosis, and inflammation in medium and large-sized arteries, and it is the main cause of cardiovascular disease (CVD). AT is caused by dyslipidemia and mediated by both innate and adaptive immune responses. Despite lipid-lowering drugs have shown to decrease the risk of cardiovascular events (CVEs), there is a significant burden of AT-related morbidity and mortality. Identification of subjects at increased risk for CVE as well as discovery of novel therapeutic targets for improved treatment strategies are still unmet clinical needs in CVD. Microvesicles (MVs), small extracellular plasma membrane particles shed by activated and apoptotic cells have been widely linked to the development of CVD. MVs from vascular and resident cells by facilitating exchange of biological information between neighboring cells serve as cellular effectors in the bloodstream and play a key role in all stages of disease progression. This article reviews the current knowledge on the role of MVs in AT and CVD. Attention is focused on novel aspects of MV-mediated regulatory mechanisms from endothelial dysfunction, vascular wall inflammation, oxidative stress, and apoptosis to coagulation and thrombosis in the progression and development of atherothrombosis. MV contribution to vascular remodeling is also discussed, with a particular emphasis on the effect of MVs on the crosstalk between endothelial cells and smooth muscle cells, and their role regulating the active process of AT-driven angiogenesis and neovascularization. This review also highlights the latest findings and main challenges on the potential prognostic, diagnostic, and therapeutic value of cell-derived MVs in CVD. In summary, MVs have emerged as new regulators of biological functions in atherothrombosis and might be instrumental in cardiovascular precision medicine; however, significant efforts are still needed to translate into clinics the latest findings on MV regulation and function. Frontiers Media S.A. 2017-12-18 /pmc/articles/PMC5741657/ /pubmed/29326946 http://dx.doi.org/10.3389/fcvm.2017.00077 Text en Copyright © 2017 Badimon, Suades, Arderiu, Peña, Chiva-Blanch and Padró. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Badimon, Lina
Suades, Rosa
Arderiu, Gemma
Peña, Esther
Chiva-Blanch, Gemma
Padró, Teresa
Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse
title Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse
title_full Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse
title_fullStr Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse
title_full_unstemmed Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse
title_short Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse
title_sort microvesicles in atherosclerosis and angiogenesis: from bench to bedside and reverse
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741657/
https://www.ncbi.nlm.nih.gov/pubmed/29326946
http://dx.doi.org/10.3389/fcvm.2017.00077
work_keys_str_mv AT badimonlina microvesiclesinatherosclerosisandangiogenesisfrombenchtobedsideandreverse
AT suadesrosa microvesiclesinatherosclerosisandangiogenesisfrombenchtobedsideandreverse
AT arderiugemma microvesiclesinatherosclerosisandangiogenesisfrombenchtobedsideandreverse
AT penaesther microvesiclesinatherosclerosisandangiogenesisfrombenchtobedsideandreverse
AT chivablanchgemma microvesiclesinatherosclerosisandangiogenesisfrombenchtobedsideandreverse
AT padroteresa microvesiclesinatherosclerosisandangiogenesisfrombenchtobedsideandreverse